All In Biotech

Drug Trial Radar · NCT03271489

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Last checked: Nov 19, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 478 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

478

Actual

Start

Sep 13, 2017

Primary completion

Jun 28, 2024

Study completion Jun 28, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized multicenter phase 3b study seeks to evaluate the safety of elagolix in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. This study was double-blind (DB) during the first 12 months and open-label (OL) for the next 36 months.

Conditions

  • Heavy Menstrual Bleeding
  • Uterine Fibroids

Interventions

  • ElagolixDrug

    Film-coated 300 mg tablets

  • Estradiol /norethindrone acetate (E2/NETA)Drug

    Estradiol 1 mg/norethindrone acetate 0.5 mg capsules

  • E2/NETA PlaceboOther

    Placebo capsules

  • Elagolix PlaceboOther

    Film-coated placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Baseline to 60 months

Locations

157 sites in 2 countries. Site status is shown where the registry gives one.

  • Alabama Clinical Therapeutics /ID# 160835

    Birmingham, Alabama

  • Alabama Clinical Therapeutics /ID# 160927

    Birmingham, Alabama

  • Choice Research, LLC /ID# 161498

    Dothan, Alabama

  • Southern Women's Specialists PC /ID# 161531

    Fairhope, Alabama

  • E Squared Research /ID# 163645

    Huntsville, Alabama

  • Women's Health Alliance of Mobile /ID# 161443

    Mobile, Alabama

  • Mobile, OBGYN P.C. /ID# 161530

    Mobile, Alabama

  • Mesa Obstetricians and Gynecologists /ID# 160955

    Mesa, Arizona

  • Noble Clinical Research /ID# 166949

    Tucson, Arizona

  • Vision's Clinical Research-Tucson /ID# 161508

    Tucson, Arizona

  • Eclipse Clinical Research /ID# 161516

    Tucson, Arizona

  • Duplicate_Core Healthcare Group /ID# 160858

    Cerritos, California

  • Diagnamics Inc. /ID# 160950

    Encinitas, California

  • HRC Fertility /ID# 161493

    Encino, California

  • SC Clinical Research /ID# 164395

    Garden Grove, California

  • Duplicate_Duplicate_Marvel Clinical Research /ID# 167297

    Huntington Beach, California

  • Grossmont Ctr Clin Research /ID# 165120

    La Mesa, California

  • Olympia Clinical Trials /ID# 201562

    Los Angeles, California

  • National Research Institute /ID# 160952

    Los Angeles, California

  • Futura Research, Org /ID# 160924

    Montebello, California

  • California Medical Research Associates /ID# 161481

    Northridge, California

  • Northern California Research /ID# 161561

    Sacramento, California

  • Precision Research Institute - San Diego /ID# 163069

    San Diego, California

  • MD Strategies Research Centers /ID# 161544

    San Diego, California

  • Health care Affiliates Medical Group /ID# 163324

    Santa Ana, California

  • Alta California Medical Group /ID# 163564

    Simi Valley, California

  • Upland Clinical Research /ID# 164528

    Upland, California

  • Bayview Research Group LLC /ID# 161484

    Valley Village, California

  • Advanced RX Clinical Research /ID# 161599

    Westminster, California

  • Emerson Clinical Research Inst /ID# 162181

    Washington D.C., District of Columbia

  • James A. Simon, MD, PC /ID# 160931

    Washington D.C., District of Columbia

  • Women's Health Partners /ID# 203577

    Boca Raton, Florida

  • David Lubetkin MD LLC /ID# 203578

    Boca Raton, Florida

  • Brandon Premier Health Care, PA/Gulf Coast Research Group, LLC /ID# 160910

    Brandon, Florida

  • Omega Research Maitland, LLC /ID# 160857

    DeBary, Florida

  • Midland Florida Clinical Research Center /ID# 161487

    DeLand, Florida

  • KO Clinical Research, LLC /ID# 160928

    Fort Lauderdale, Florida

  • Sweet Hope Research Specialty Inc /ID# 163522

    Hialeah, Florida

  • Solutions Through Adv Rch /ID# 160935

    Jacksonville, Florida

  • Altus Research, Inc /ID# 160912

    Lake Worth, Florida

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.